MD Anderson study finds patients with aberrations in two genes respond better to drugs blocking a well-known cancer pathway
Cancer patients with mutations or variations in two genes -– PIK3CA and PTEN -– who have failed to respond to several standard treatments, respond significantly better to anti-cancer drugs that inhibit these genes’ pathways of action, according to research from the MD Anderson Cancer Center presented at the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland.
Among the research institutions NCI funds across the United States, it currently designates 67 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.